|
| Monday, March 31, 2025 |
|
|
Yunkang's Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024 |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of "in-depth services and lean operations", promoted development with innovation, deepened integrated collaboration among "government, industry, academy, research, medicine, application", accelerated digital application of "AI + medical care", continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience. more info >> |
|
|
雲康集團2024年醫聯體共建業務及特檢項目收益佔比持續增長 |
| 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2024年12月31日止年度（「報告期」）之全年業績。本年度，集團堅定執行「深度服務、精益運營」的總體經營方針，以創新促進發展，深化「政產學研醫用」一體化協同，加快「AI+醫療」數智化應用，持續加強精細化管理，降本增效，展現出強大的經營韌性。 more info >> |
|
| Wednesday, August 28, 2024 |
|
|
Yunkang Group's 2024 Interim Revenue Reaches Approximately RMB380 Million |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2024 (the "Reporting Period"). In the first half of 2024, the Group continued to deeply implement its overall business philosophy of 'in-depth services and lean operations'. more info >> |
|
|
雲康集團2024年中期收益達約人民幣3.80億元 |
| 領先的中國醫學運營服務應供商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2024年6月30日止（「報告期」）之中期業績。2024上半年，集團繼續深入執行「深度服務、精益運營」的總體經營方針，一方面持續深化醫聯體診斷檢測服務模式、快速複製醫檢聯合創新平台，打造創新醫療中心新模式，聚焦「AI+醫療」，在產品創新和模式創新方面成效明顯，推動行業高質發展；另一方面，以快速發展的數字化技術為抓手，堅持降本增效，持續打造精益化運營能力。 more info >> |
|
| Friday, July 5, 2024 |
|
|
Hong Kong Investor Relations Association Announces Winners of the 10th IR Awards 2024 |
| The Hong Kong Investor Relations Association ("HKIRA") today announced the winners of the 10th Investor Relations Awards 2024 (the "IR Awards" or the "Awards"). more info >> |
|
| Friday, March 31, 2023 |
|
|
云康集团公布上市后首份全年业绩 |
| 领先的中国医学运营服务应供商云康集团有限公司（「云康」或「集团」；股份代号：2325）公布截至2022年12月31日止年度（「报告期」）之上巿后首份全年业绩。 more info >> |
|
|
云康集团公佈上市後首份全年業績 |
| 領先的中國醫學運營服務應供商云康集团有限公司（「云康」或「集團」；股份代號：2325）公布截至2022年12月31日止年度（「報告期」）之上巿後首份全年業績。 more info >> |
|
|
Yunkang Group Announces First Annual Results Since Listing |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its first annual results for the year ended December 31, 2022 (the "Reporting Period") since its listing. more info >> |
|
| Wednesday, October 26, 2022 |
|
|
云康集团（02325.HK）荣获香港股票分析师协会《上市公司年度大奖2022》 |
| 中国领先医学运营服务提供商－云康集团有限公司（「云康集团」或「集团」）（股票编号：02325.HK）荣获香港股票分析师协会颁发的《上市公司年度大奬2022》，以表扬集团于业务营运及投资者关系工作的卓越表现。 more info >> |
|
|
雲康集團（02325.HK）榮獲香港股票分析師協會《上市公司年度大奬2022》 |
| 中國領先醫學運營服務提供商－雲康集團有限公司（「雲康集團」或「集團」）（股票編號：02325.HK）榮獲香港股票分析師協會頒發的《上市公司年度大奬2022》，以表揚集團於業務營運及投資者關係工作的卓越表現。 more info >> |
|
|
|
|
